Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heinz-Josef Lenz

Medical Oncology Los Angeles, CA Medical Doctor

NPI 1700814209 CMS profile 838537

1441 Eastlake Ave., Nor 8302E, Los Angeles, CA 90033

Open in the dashboard

General payments

$185,202

151 records reported · program years 2019–2025

Research payments

$7,860

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,381,012 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Heinz-Josef Lenz of Los Angeles, CA is reported in the CMS Open Payments database as having received $185,202 across 151 general payments and $7,860 in research payments paid to them. Separately, studies naming them as principal investigator received $11,381,012 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81,732 50
2025 Research $2,180 2
2024 General $32,708 38
2024 Research $3,980 2
2023 General $16,369 10
2022 General $9,797 12
2021 General $10,490 8
2021 Research $1,700 2
2020 General $8,206 9
2019 General $25,900 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heinz-Josef Lenz
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Heinz-Josef Lenz were reported at $81,732. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Heinz-Josef Lenz Medical Oncology median Middle half National median
2019 $25,900 $968 $140–$6,658 $163
2020 $8,206 $747 $102–$5,891 $114
2021 $10,490 $430 $50–$4,098 $132
2022 $9,797 $812 $127–$4,907 $149
2023 $16,369 $957 $144–$5,248 $160
2024 $32,708 $1,042 $149–$5,650 $164
2025 $81,732 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $54,779 56 payments
  2. Merck Sharp & Dohme Corporation $33,744 11 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $29,081 27 payments
  4. BioNTech SE $14,754 7 payments
  5. EMD Serono Research & Development Institute, Inc. $14,593 2 payments
  6. AbbVie, Inc. $10,995 15 payments
  7. GlaxoSmithKline, LLC. $5,373 6 payments
  8. G1 Therapeutics, Inc. $4,222 3 payments
  9. Boehringer Ingelheim International GmbH $3,119 4 payments
  10. Jazz Pharmaceuticals Inc. $2,750 1 payment
  11. Other $11,792 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $119,126 49 payments
  2. Travel and Lodging $52,448 46 payments
  3. Education $5,206 8 payments
  4. Honoraria $3,840 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,564 3 payments
  6. Food and Beverage $2,018 44 payments
Products named General payments · program years 2019–2025
  1. Stivarga $11,802 11 payments
  2. COSELA $4,222 3 payments
  3. Nexavar $2,500 5 payments
  4. Vitrakvi $2,158 4 payments
  5. Envarsus $2,000 2 payments
  6. BIZENGRI $2,000 1 payment
  7. BRUKINSA $1,500 1 payment
  8. ENHERTU $1,250 1 payment
  9. ORENCIA $615 1 payment
  10. Datroway $28 1 payment
  11. Other $111 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $6,160 4 payments
  2. F. Hoffmann-La Roche AG $1,700 2 payments

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$34,847

Medicare's payments for the services billed

Medicare patients

82

Average age 73

Services billed

561

35 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 74%
Ischemic heart disease 51%
Arthritis 49%
Diabetes 38%
Chronic kidney disease 32%
Depression 26%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record